News & Views

  • Companies Pledge Funds to Accelerate Drug Discovery Process
    Dario Alessi

Companies Pledge Funds to Accelerate Drug Discovery Process

Aug 12 2020 Read 168 Times

Funding of £7.5 million by three of the world’s leading pharmaceutical companies will enable the University of Dundee’s Division of Signal Transduction Therapy (DSTT) to continue its award-winning work.

Pharmaceutical giants Boehringer Ingelheim, GlaxoSmithKline and Merck KGaA, Darmstadt, Germany, will provide the financial support for fundamental research in multiple therapeutic areas, including cancer, arthritis, lupus, hypertension and Parkinson’s disease. This new round of funding will support dozens of posts at Dundee for the next four years.

The DSTT comprises 23 research teams at Dundee’s School of Life Sciences, 13 of which are based within the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU).

Founded in 1998, expanded in 2003 and renewed in 2008, 2012 and 2018, the DSTT is the world’s longest running collaboration between academic research laboratories and the pharmaceutical industry. The latest renewal means the consortium has attracted more than £65 million in funding since its inception. It is widely regarded as a model for how academia and industry can interact productively for which it was awarded a Queen’s Anniversary Prize for Higher Education in 2006.

DSTT Director Professor Dario Alessi said, “It is incredibly exciting that we have succeeded in renewing our flagship collaboration with our pharmaceutical partners that has been ongoing for the last 22 years. This renewal reflects the high quality and importance of the research that our Dundee-based scientists are making to advance understanding of human diseases such as Parkinson’s, immune disorders and cancer. 

“This renewal is a tremendous boost for our research and will secure well-paid jobs at the University of Dundee. It provides our students and postdoctoral researchers with vital experience that will encourage some of them to embark on a lifelong career in drug discovery.”

The DSTT works to help identify new drug targets and then accelerate the early phase development of improved treatments for major global diseases. It helps the participating pharmaceutical companies to develop improved drugs that target major ‘controller’ proteins in the body, focusing on enzymes called kinases and components of the ubiquitin system.

Further information

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

LabAsia Buyers Guide 2020

October 2020

In This Edition Articles - Ambient Ionisation MS and GC-MS Analysis and Identification of Aroma Compounds in Agave Based Alcoholic Beverages - How a Chromatographic Method is More Than a Sep...

View all digital editions


West Africa Water Expo

Oct 06 2020 Lagos, Nigeria


Oct 06 2020 Digital Forum


Oct 07 2020 Lyon, France


Oct 07 2020 Lausanne, Switzerland

View all events